Matrix Metalloproteinase 9/microRNA-145 Ratio: Bridging Genomic and Immunological Variabilities in Thyroid Cancer

Area of Science:

• Oncology
• Biomarker Discovery
• Molecular Diagnostics

Background:

• Matrix metalloproteinase 9 (MMP9) and microRNA-145 (miR-145) are key players in thyroid cancer progression.
• Their combined clinical utility as a unified prognostic marker across diverse thyroid cancer subgroups is not well understood.
• Patient heterogeneity due to genetic mutations or autoimmune status complicates prognostication.

Purpose of the Study:

• To investigate the diagnostic and prognostic value of the MMP9/miR-145 ratio in thyroid cancer.
• To determine if this ratio can overcome inter-patient heterogeneity.
• To assess its utility as a versatile biomarker irrespective of genetic or autoimmune status.

Main Methods:

• MMP9 and miR-145 expression analyzed in 175 paired papillary thyroid cancer (PTC) and normal tissues.
• Plasma levels assessed perioperatively and longitudinally in 86 PTC patients.
• Associations with clinicopathological parameters and patient outcomes evaluated.

Main Results:

• MMP9 was upregulated, miR-145 downregulated in cancer tissues, leading to a 17.6-fold higher MMP9/miR-145 ratio in tumors.
• The tissue ratio diagnosed malignancy irrespective of BRAF mutation or Hashimoto's thyroiditis.
• High preoperative plasma ratio correlated with aggressive features and unfavorable outcomes, but had limited post-surgical monitoring utility.

Conclusions:

• The MMP9/miR-145 ratio is a promising biomarker for PTC, bridging genetic and immunological variabilities.
• It enhances preoperative diagnosis and prognostication across diverse patient subgroups, stratifying cases by aggressiveness.
• Further validation is needed for clinical translation in personalized thyroid cancer management.